netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Researchers ID Key Compounds Related to Blood Vessel Growth in Wet AMD

A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by RPB-supported researchers at Massachusetts Eye and Ear. The report, published online in the Proceedings of the National Academy of Sciences, suggests that it may be possible to prevent the vision loss observed in wet AMD by increasing the expression of specific bioactive lipid metabolites in the retina.

Choroidal neovascular lesion with associated blood vessels (red) and immune cells (Green). Photo courtesy: Dr. Kip Connor.

Disease-causing angiogenesis is a feature of advanced AMD in which blood vessels in the retina (the structure in the back of the eye that senses and perceives light) begin to grow new, abnormal blood vessels on the surface of the retina. These new vessels are immature, and can leak, rupture, or cause retinal detachment. Such cases, termed neovascular or “wet” AMD, account for 10 to 15 percent of AMD cases, develop abruptly, and rapidly lead to substantial vision loss.

The research demonstrates that bioactive lipids have the ability to regulate inflammatory immune cells in the retina, key regulators of the angiogenic process in this disease. Given this, these molecules show promising therapeutic potential not only for AMD, but also for other major conditions that involve angiogenesis and inflammation, such as cardiovascular disease and cancer.

“Given the high prevalence and progressive nature of neovascular eye disease, the ability to stabilize bioactive lipids that mitigate or halt disease is of great and increasingly therapeutic significance,” said corresponding author and RPB grantee Kip Connor, PhD, a vision scientist at Mass. Eye and Ear and Assistant Professor of Ophthalmology at Harvard Medical School. “It is our hope that emerging technologies and future studies will expand on our work, and ultimately lead to safe, targeted, and cost-effective therapies that markedly improve visual outcomes and quality of life for patients suffering from these debilitating eye diseases.”

Read the full press release from Mass. Eye and Ear

Related News: Feature Story, Macular Degeneration, Retina Disorders , Top Story

Dr. Semenza and colleague work in his lab

Research to Prevent Blindness Grantee Dr. Gregg Semenza Wins Nobel Prize in Medicine

Dr. Semenza is being recognized for his discoveries related to how cells respond to low oxygen levels, which have implications for the treatment of cancer, eye diseases and more.

Read More

 
RPB logo

RPB and Partners Award $1.2 Million In Grants for Novel AMD Research

Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.

Read More

 
CDA 30th Anniversary book

The Career Development Award Turns 30: Celebrating a Generation of Support for Early-Career Scientists

CDA founded 30 years ago as one of the few private sources of funding aimed specifically at early-career vision researchers.

Read More

 
Retinal image of person with Alzheimer's disease

Could An Eye Exam Reveal Alzheimer’s Disease?

Study from RPB-supported researchers at Duke University suggests loss of blood vessels in retina reflect changes in brain health.

Read More

 
Gregory Schwartz in the lab

New Findings on Blood Vessel Regulation

A study from an RPB-supported researcher at Northwestern University School of Medicine could speed up the diagnosis of retinal diseases.

Read More

 
NEI Audacious Goals image and text

RPB-SUPPORTED RESEARCHERS INTEGRAL TO NEI’S AUDACIOUS GOALS INITIATIVE

Vision scientists who have received RPB funding will help lead all five research teams, which will seek to accelerate development of regenerative treatments for blindness.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.